Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 69% of modeled bridge. Strengths: Revenue per Bed, Payer Diversity. Risks: Commercial Payer %. Risk-adjusted uplift: $20.7M (vs $29.9M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $11.4M | $11.4M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $11.0M | $313K | $11.3M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $1.7M | $5.2M | $6.9M | $21.8M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $364K | $364K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 30.9% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $2.8M | $5.7M | $8.5M | $11.4M | $11.4M | $11.4M | $11.4M |
| Denial Rate Reduction | $0 | $2.8M | $5.6M | $8.5M | $11.3M | $11.3M | $11.3M | $11.3M |
| A/R Days Reduction | $0 | $2.3M | $4.6M | $6.9M | $6.9M | $6.9M | $6.9M | $6.9M |
| Clean Claim Rate | $0 | $182K | $364K | $364K | $364K | $364K | $364K | $364K |
| Cumulative | $0 | $8.2M | $16.3M | $24.3M | $29.9M | $29.9M | $29.9M | $29.9M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $29.9M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 59% / 10.1x | 63% / 11.6x | 67% / 13.1x | 69% / 13.8x | 71% / 14.6x |
| 9.0x | 54% / 8.6x | 58% / 9.9x | 62% / 11.3x | 64% / 11.9x | 66% / 12.6x |
| 10.0x | 49% / 7.4x | 54% / 8.6x | 58% / 9.8x | 60% / 10.4x | 62% / 11.0x |
| 11.0x | 45% / 6.5x | 50% / 7.5x | 54% / 8.6x | 56% / 9.2x | 58% / 9.7x |
| 12.0x | 41% / 5.7x | 46% / 6.6x | 50% / 7.6x | 52% / 8.1x | 54% / 8.6x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline 22% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 5.1x, adding 3.4 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $44.9M | — | $44.9M | 7.9% |
| Year 1 | $46.2M | +$20.0M | $66.2M | 11.6% |
| Year 2 | $47.6M | +$29.9M | $77.6M | 13.6% |
| Year 3 | $49.1M | +$29.9M | $79.0M | 13.9% |
| Year 4 | $50.5M | +$29.9M | $80.5M | 14.1% |
| Year 5 | $52.1M | +$29.9M | $82.0M | 14.4% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $5.7M | $8.5M | $11.4M | $13.7M |
| Denial Rate Reductio | $5.6M | $8.5M | $11.3M | $13.5M |
| A/R Days Reduction | $3.5M | $5.2M | $6.9M | $8.3M |
| Clean Claim Rate | $182K | $273K | $364K | $437K |
| Total | $15.0M | $22.5M | $29.9M | $35.9M |
Peer Context — Where This Hospital Sits
Key metrics vs 80 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 7.9% | -9.3% | 1.0% | 7.1% | P77 |
| Net-to-Gross | 58.9% | 21.8% | 26.9% | 30.8% | P99 |
| Occupancy | 56.0% | 49.9% | 57.1% | 73.3% | P45 |
| Rev/Bed | $3.1M | $966K | $1.4M | $1.7M | P96 |
| Exp/Bed | $2.9M | $829K | $1.3M | $1.7M | P96 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.